Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.

ABSTRACT:

Background

Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients.

Objectives

The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23.

Design

Multicenter, open-labeled, randomized controlled study.

Setting

Seven university-affiliated hospitals in Korea.

Participants

Overall, 66 peritoneal dialysis patients were enrolled.

Intervention

Sixty six patients were randomly assigned to treatment with either cinacalcet + oral vita

SUBMITTER: Kim HJ 

PROVIDER: S-EPMC3669111 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature